Latest Articlesddd

Why Scientists Are Now Optimistic Zeroing in on Neurodegenerative Diseases

August 24, 2017 0

New Discoveries in Neurodegenerative Diseases  Everyday is another day that can totally differ from the previous …

The STAR of the Week

August 20, 2017 1

THE WEEK IN REVIEW Wall Street As we said in yesterday’s article posted under Today’s Highlights, …

Why Sangamo Rallied

August 18, 2017 2

About Our New Section On Sunday, August 20, 2017 we will post our first “The Week …

Stocks’ Declines That Offer Real Opportunities for Accumulation at Bargain Prices

August 15, 2017 0

AFTER MANY OF THE PROHOST PICKED STOCKS NEARED REACHING THE PROHOST NEAR-TERM TARGETS, recently, external circumstances …

About Exelixis’ Transition

August 8, 2017 0

EXELIXIS Exelixis’ (EXEL) shareholders know well how good are the firm’s announced financial results for the …

Reasons for Vertex’s & Illumina’s Outperformance

August 7, 2017 0

Synopsis Most of the Prohost picked stocks gained momentum and closed higher at the end of …

Prohost Letter #412 Part 3

August 3, 2017 0

Prohost Letter #412 Part 3 GLIOBLASTOMA - Is There Hope? Senator John McCain was diagnosed with a …

An Approval for Celgene and Two Breakthrough Designations for AstraZeneca

August 2, 2017 0

CELGENE Good news from Celgene (CELG) announced  that the FDA approved the firm’s targeted drug Idhifa (enasidenib) for …

Prohost Letter #412 Part 2

July 27, 2017 0

Prohost Letter #412 Part 2 Living Breakthroughs in The Making - Understanding the origin of diseases …

Amgen Outperformed and Will Continue to Outperform

July 26, 2017 0

Amgen’s (AMGN) stock outperformed in the past 6 months for significant reasons and these reasons are …

Why Eli Lilly Wanted Nektar’s Drug NKTR-358 So Badly. Incyte’s Most Recent News

July 25, 2017 0

It took only a few months after the dosing stages of NKTR-358 in in a Phase …

Prohost Letter #412 Part 1

July 24, 2017 0

Prohost Letter #412 Part 1 Updating Our Targets - This Letter will be of three parts. …

Theravance Biopharma Has Good News for COPD Patients

July 21, 2017 0

Theravance Biopharma (TBPH) and Mylan N.V. (MYL) announced positive results from a 12-month Phase 3 safety …

Vertex: A Cystic Fibrosis Institution with a Bright Future

July 20, 2017 0

Yesterday, Wednesday July 19, Vertex’s (VRTX) stock added over 20% to its value, recording a new …

Developing Another Better CAR Using NK Cells Instead of T Cells. Nektar Has Great News

July 19, 2017 0

IMPROVING ON CAR IMMUNOTHERAPY APPROACH  When we stated that chimeric antigen receptor CAR immunotherapy process was …

The Meaning of a 10-0 Vote in Favor of Novartis’ CAR T-Cell Therapy Approval.

July 13, 2017 0

A BIG YES for Novartis CAR-T product has come from the  Food and Drug Administration (FDA) advisory …

Arena’s Successful Pulmonary Arterial Hypertension Drug. Novartis CAR-T Product Review for Approval Tomorrow

July 11, 2017 0

Arena (ARNA) announced positive Phase 2 clinical trial results for its drug ralinepag1 for pulmonary arterial hypertension …

Targeted Drugs That Would Improve on Immunotherapy Treatments’ Outcomes. See Array and Exelixis

July 10, 2017 0

FROM ARRAY Array’s Drug Binimetinib in Combination Therapy with Merck’s Drug Keytruda for METASTATIC FOR COLORECTAL …

Celgene and Immunotherapy: An Unfolding Story

July 8, 2017 0

As we wrote yesterday, immunotherapy checkpoint inhibitors represent a great advancement and big changes in the …

Merck’s Keytruda: Extremely Valuable, But Not for Multiple Myeloma

July 6, 2017 0

Merck’s (MRK) anti-PD-1 drug Keytruda® (pembrolizumab) is approved for many, many cancers. Yet, it is fair …